Drug Trial Radar · NCT00000766
CMV Retinitis Retreatment Trial
Last checked: Nov 19, 2026Latest source record: Mar 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Not stated
Primary completion
Sep 1995
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and efficacy of three therapeutic regimens (foscarnet, ganciclovir, or the combination) for recurrent or persistent AIDS-related cytomegalovirus (CMV) retinitis. Although therapy with foscarnet or ganciclovir halts retinitis progression in 90 percent of patients treated, relapses are common and may accelerate due to development of drug resistance, deteriorating immune function, or other factors. Treatment strategies currently being investigated include switching patients from one drug to the other or combining the two drugs.
Conditions
- Cytomegalovirus Retinitis
- HIV Infections
Interventions
Foscarnet sodiumDrug
GanciclovirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCSD - Shiley Eye Ctr / SOCA
La Jolla, California
UCLA - Jules Stein Eye Institute / SOCA
Los Angeles, California
UCSF - San Francisco Gen Hosp
San Francisco, California
Northwestern Univ / SOCA
Chicago, Illinois
Johns Hopkins Hosp / SOCA
Baltimore, Maryland
New York Univ Med Ctr / SOCA
New York, New York
New York Hosp - Cornell Med Ctr / Sloan - Kettering / SOCA
New York, New York
Mount Sinai Med Ctr / SOCA
New York, New York
Univ of North Carolina / SOCA
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.